AAV9-Mediated Gene Therapy for Infantile-Onset Pompe's Disease.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40561529.
- Also identified by DOI 10.1056/NEJMoa2407766.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Four patients with infantile-onset Pompe's disease received a single intravenous injection of an adeno-associated virus serotype 9 vector carrying codon-optimized complementary DNA encoding human acid α-glucosidase (GAA) (dose, 1.2 × 10<sup>14</sup> vector genomes per kilogram of body weight). One patient was withdrawn from the study and subsequently died. The other patients had improvement in cardiac outcomes and motor function over a 52-week observation period. Anti-GAA antibodies were not detected in any of the patients during the observation period. Respiratory tract infections were the most common adverse events. (Funded by the National Natural Science Foundation of China and National High Level Hospital Clinical Research Funding; Chinese Clinical Trial Registry number, ChiCTR2200063229.).
Medical subject headings
- alpha-Glucosidases
- Dependovirus
- Genetic Therapy
- Genetic Vectors
- Glycogen Storage Disease Type II